Laurence Katznelson

Clinical Focus

• Cancer > Neuro Oncology
• Endocrine
• Endocrine - Endocrinology
• Endocrinology
• Multiple Endocrine Neoplasias

Administrative Appointments

• Chair, Special Programs Committee, Endocrine Society (2008 - present)
• Director, Endocrinology Fellowship Training Program, Stanford (2005 - present)
• Medical Director, Stanford Pituitary Center (2004 - present)

Honors and Awards

• Best Doctors in America, Best Doctors (2005-)

Professional Education

Postdoctoral Advisees

Ronadip Banerjee, Era Shah

Graduate & Fellowship Program Affiliations

• Medicine

Web Site Links

• The Pituitary Center at Stanford

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Research Interests

My clinical and research interests in neuroendocrinology include the following programs:

1. Investigations into the effects of brain injury on pituitary function, with emphasis on the impact of hypopituitarism on rehabilitation

2. Research on the effects of neuroendocrine factors, including growth hormone and glucocorticoids, on neurocognitive function

3. Investigations into novel therapeutic modalities for acromegaly and hypopituitarism

4. Research into the effects of anabolic hormones such as gonadal steroids and growth hormone on body composition

Clinical Trials

• A multicenter, randomized, blinded study to assess safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegaly Recruiting
• A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurrent Cushing's disease Recruiting
• Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults Recruiting
• Efficacy and Safety Study of CORLUX (mifepristone) in the Treatment of Endogenous Cushing’s Syndrome Recruiting
• PHASE III, OPEN-LABEL, MULTICENTER INTERNATIONAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN OCTREOTIDE IMPLANT VERSUS SANDOSTATIN LAR® DEPOT IN PATIENTS WITH ACROMEGALY Recruiting

Publications

• Non-surgical management of hormone-secreting pituitary tumors. Patil CG, Hayden M, Katznelson L, Chang SD. J Clin Neurosci. 2009; 16 (8): 985-93
• Prevalence and clinical demographics of cerebral salt wasting in patients with aneurysmal subarachnoid hemorrhage. Kao L, Al-Lawati Z, Vavao J, Steinberg GK, Katznelson L. Pituitary. 2009; 12 (4): 347-51
• Alterations in body composition in acromegaly. Katznelson L, Pituitary. 2009; 12 (2): 136-42
• Lanreotide promotes apoptosis and is not radioprotective in GH3 cells. Ning S, Knox SJ, Harsh GR, Culler MD, Katznelson L. Endocr Relat Cancer. 2009; 16 (3): 1045-55
• Endogenous NIS expression in triple-negative breast cancers. Renier C, Yao C, Goris M, Ghosh M, Katznelson L, Nowles K, Gambhir SS, Wapnir I. Ann Surg Oncol. 2009; 16 (4): 962-8